Photo of Jeanne Link, M.S., Ph.D.

Jeanne Link M.S., Ph.D.

  •      (503) 494-1851
    • Professor of Diagnostic Radiology, Division of Nuclear Medicine School of Medicine
    • Director Center for Radiochemistry Research School of Medicine

Jeanne Link is the Director for the Center for Radiochemistry Research at Oregon Health & Science University and has worked on development of new radiopharmaceuticals for three decades. She received her BS from the University of California at Davis in Biological Sciences, a MS in Radiation Ecology and PhD in Analytical and Radiochemistry from University of Washington. She led PET radiochemistry operations at the University of Washington for 20 years prior to moving to OHSU in 2014.

Dr. Link’s scientific goals include molecular imaging using gamma emitting radiation, which is the most sensitive noninvasive method available to evaluate most biochemical pathways in vivo. When a radiolabeled chemical or quantitative biochemical is injected and used with positron emission tomography (PET) imaging, a temporal and spatial distribution of the compound throughout the body is obtained. The Center for Radiochemistry Research makes radiolabeled compounds that target specific pathways in the body, such as parts of signaling systems, including the transmitters and receptors and enzymes in those pathways. Other compounds can show the spatial distribution of a drug throughout the body and there are a myriad of other potential targets. The limit of the technique is how carefully we ask the question about a disease. Dr. Link's work focuses on translating what has been learned in cellular work and animal studies to further research in animal models and human imaging studies. This leads to a better understanding of the mechanisms, extent and phenotype of diseases. This work improves understanding of disease and drugs in vivo to select appropriate treatment for an individual therapy, thereby improving outcome.

Read more

Areas of interest

  • Partnering with scientists to understand the spatial and functional status of biological systems in vivo
  • Working with scientists to detect the extent and amount of disease in vivo
  • Collaborating with radiochemistry experts to develop image analysis techniques
  • Working with scientists to analyze response to radiation therapies
  • Development of new radiochemistry methods and radiopharmaceuticals
  • Enhancing radiochemistry by developing and simplifying automated radiosynthesis
  • Advancing radiochemistry by developing more robust and streamlined techniques

Education

  • B.S., University of California Davis, Davis California United States 1974
  • M.S., University of Washington, Seatte Washington United States 1982
  • Ph.D., University of Washington, Seattle Washington United States 1998

Memberships and associations

  • American Chemical Society
  • Society of Nuclear Medicine
  • International Society of Radiopharmaceutical Sciences
  • American Society of Nuclear Cardiology

Publications

Selected publications

  • Link JM, Krohn KA, Eary JF, Kishore R, Lewellen TK, Johnson MW, Badger CC, Richter KY, Nelp WB. 89Zr for antibody labeling and positron emission tomography. J. Label Comp Radiopharm 23: 1297-1298, 1986.

  • Link JM, Synovec RE. Whole Column Radioactivity Detection: Simultaneous Separation and Enhanced Detectability. Anal Chem. 71(14):2700-2707, 1999. PMID: 10424163

  • Link JM, Stratton JR, Levy WC, Poole JE, Shoner SC, Stuetzle W, Caldwell JC. PET Measures of Pre- and Post-synpatic Cardiac Beta Adrenergic Function. Nucl. Med. & Biol. 30(8):795-803, 2003. PMID: 14698782

  • Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat, JD.  Imaging p-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol. Ther. 77: 503-514, 2005, PMID: 15961982

  • Mann GN, Link JM, Pickett CA, Byrd DR, Kinahan PE, Krohn KA, Mankoff DA. [C-11]meta-hydroxyephedrine and [F-18] fluorodeoxyglucose positron emission tomography improves clinical decision making in suspected pheochromocytoma. Annals Surg Oncol 13: 187 – 197, 2006. PMID: 16418883

  • Linden HM, Stekhova S, Link JM, Gralow JR, Livingston RB, Ellis GK, Peterson LM. Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative fluoroestradiol (FES) PET imaging predicts response to endocrine treatment. J Clin Oncol, 24:2793:2799, 2006. PMID: 16682724

  • Link JM, Caldwell JH. Diagnostic and prognostic imaging of the cardiac sympathetic nervous system. Nat Clin Pract Cardiovasc Med. 5 Suppl 2:S79-86, 2008. PMID: 18641611

  • Eyal S, Ke B, Muzi M, Link JM, Mankoff DA, Collier AC, Unadkat JD. Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther 2010 May; 87(5):579-85. Epub 2010 Mar 24. PMID: 20336065

  • Eary JE, Link JM, Muzi M, Conrad EU, Mankoff DA, White JK, Krohn KA. Multiagent PET for Risk Characterization in Sarcoma. J. Nucl Med. 2011 Apr; 52(4):541-546. PMID: 21421714

  • Deo Anand K., Borson Soo, Jeanne M. Link, Karen Domino, Janet F. Eary, Ban Ke, Todd L. Richards, David A. Mankoff, Satoshi Minoshima, Finbarr O’Sullivan, Sara Eyal, Peng Hsiao, Ken Maravilla, Jashvant D. Unadkat.   Activity of P-glycoprotein, a b-amyloid Transporter at the Blood-Brain Barrier, is Compromised in  Patients with Mild Alzheimer’s Disease. J. Nucl Med & Molec Imag.   May 19; 55 (7):1106-111, 2014. PMID: 24842892

Publications

  • "Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG" Journal of Nuclear Medicine March 1998
  • "Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis" Journal of Nuclear Medicine  2005
  • "Kinetic analysis of 2-[11C]thymidine PET imaging studies" Journal of Nuclear Medicine April 1999
  • "Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds" Journal of Nuclear Medicine  1992
  • "Site-specific labeling of annexin V with F-18 for apoptosis imaging" Bioconjugate Chemistry August 2008
  • "NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas" Molecular Imaging and Biology  2008
  • "Modeling cyclosporine a inhibition of the distribution of a P-glycoprotein PET ligand, 11-Cverapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate" Journal of Nuclear Medicine March 1 2013
  • "Reply" Clinical Pharmacology and Therapeutics September 2006
  • "Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer" Clinical Cancer Research July 15 2011
  • "A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)" Molecular Imaging and Biology  2014
  • "The relative importance of background and signal in quantifying chromatographic radioanalytes" Journal of Labelled Compounds and Radiopharmaceuticals  1999
  • "Tumor-specific positron emission tomography imaging in patients" Clinical Cancer Research June 15 2007
  • "Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate" Journal of Nuclear Medicine May 1 2009
  • "Validity of microsphere depositions for regional myocardial flows" American Journal of Physiology - Renal Fluid and Electrolyte Physiology  1987
  • "Quantitation of presynaptic cardiac sympathetic function with carbon- 11-meta-hydroxyephedrine" Journal of Nuclear Medicine  1998
  • "PET measures of pre- and post-synaptic cardiac beta adrenergic function" International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology November 2003
  • "Interpreting enzyme and receptor kinetics" International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology November 2003
  • "Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol" Journal of Nuclear Medicine March 1 2008
  • "Regional hypoxia in glioblastoma multiforme quantified with [ 18F] fluoromisonidazole positron emission tomography before radiotherapy" Clinical Cancer Research May 1 2008
  • "Molecular imaging of hypoxia" Journal of Nuclear Medicine June 1 2008
  • "Positron emission tomography imaging of tissue P-glycoprotein activity during pregnancy in the non-human primate" British Journal of Pharmacology January 2010
  • "More collaboration needed between drug development and imaging communities" Drug Discovery Today May 1 2001
  • "18F-FDG kinetics in locally advanced breast cancer" Journal of Nuclear Medicine November 1 2004
  • "Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer" Journal of Clinical Oncology June 20 2006
  • "2-[18F]fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy" Clinical Cancer Research April 1 2002
  • "Synthesis of tritiated diborane and cryptand [2.2.2]" Journal of Labelled Compounds and Radiopharmaceuticals  1990
  • "Improved methodology for a sea urchin sperm cell bioassay for marine waters" Archives of Environmental Contamination and Toxicology January 1987
  • "High speed liquid chromatography of phenylethanolamines for the kinetic analysis of [11C]-meta-hydroxyephedrine and metabolites in plasma" Journal of Chromatography B: Biomedical Sciences and Applications May 23 1997
  • "Publish or perish. .but where? What is the value of impact factors?" International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology May 1 2015
  • "PET imaging of oatp-mediated hepatobiliary transport of [11C] rosuvastatin in the rat" Molecular Pharmaceutics August 4 2014

Additional information

Edit profile